Journal of drugs in dermatology : JDD

Sixty Years of Benzoyl Peroxide Use in Dermatology.  22:54-59. 2023

Therapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US.  20:1076-1084. 2021

Efficacy of Topical Herbal Anti-inflammatory Treatment (HAT1) for Treating Psoriasis: An Investigator-Initiated Open Label Study.  20:912-913. 2021

Pediatric Lichen Planopilaris Treated With Pioglitazone: A Case Study and Literature Review.  20:779-782. 2021

Effect of ixekizumab on patient reported outcomes and quality of life in patients with moderate-to-severe plaque psoriasis: 5-year results from the UNCOVER-1 and -2 studies.  20:394-401. 2021

Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Pediatric Patients.  19:867-872. 2020

Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis.  19:741-746. 2020

Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females.  19:504-514. 2020

Injection site necrosis and ulceration following vaccination in an adult patient.  17:364-367. 2018

Is severity of disease a prognostic factor for cure following treatment of onychomycosis?.  17:175-178. 2018

A phase 2, controlled, dose-ranging study of SB208, an investigational topical nitric oxide-releasing drug, for the treatment of tinea pedis.  17:888-893. 2018

Onychomycosis: Does cure equate to treatment success?.  15:626-632. 2016

Onychomycosis: Strategies to minimize recurrence.  15:279-282. 2016

Polypodium leucotomos - An overview of basic investigative findings.  15:224-228. 2016

Identifying Signs of Tinea Pedis: A Key to Understanding Clinical Variables.  14:s42-s47. 2015

Identifying Signs of Tinea Pedis: A Key to Understanding Clinical Variables..  14:s42-s47. 2015

Pulmonary cryptococcosis in the setting of tofacitinib therapy for psoriasis.  14:901-902. 2015

Report of a case of a dermatophytoma successfully treated with topical efinaconazole 10% solution.  14:524-526. 2015

Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space.  13:1394-1398. 2014

A randomized, double-blinded trial evaluating the efficacy and tolerability of vectical ointment (calcitriol 3 mcg/g ointment) when compared to betamethasone diproprionate ointment (64 mg/g) in patients with nail psoriasis.  13:912-915. 2014

Ablative fractionated CO2 resurfacing yields excellent result for severely atrophic traumatic scar on the face.  13:861-862. 2014

Econazole nitrate foam 1% for the treatment of tinea pedis: Results from two double-blind, vehicle-controlled, phase 3 clinical trials.  13:803-808. 2014

Paraneoplastic pityriasis rubra pilaris as the presenting manifestation of metastatic squamous cell carcinoma.  13:610-612. 2014

The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: A pooled analysis of two phase 3 randomized trials.  13:815-820. 2014

Nail findings board review.  12:705-706. 2013

Program spotlight: The University of Alabama at Birmingham Department of Dermatology Residency Training Program.  12:699-700. 2013

Resident Rounds. Part III B: tumor necrosis factor-α antagonists and alopecia areata: a class-wide adverse effect..  12:713-714. 2013

Tumor necrosis factor-α antagonists and alopecia areata: A class-wide adverse effect.  12:713-714. 2013

Onchomycosis: an overview..  12. 2013

Palmoplantar pustulosis with fulminant dystrophic 20-nail psoriasis in a patient receiving adalimumab therapy.  12:16-17. 2013

Sarcoidosis as an adverse effect of tumor necrosis factor inhibitors.  11:609-612. 2012

An open-label study of the safety and efficacy of sertaconazole nitrate in the treatment of seborrheic dermatitis.  10:895-899. 2011

Wong type dermatomyositis: 20^th case reported.  9:1475-1476. 2010

Long-term safety and efficacy of etanercept in patients with psoriasis: An open-label study.  9:928-937. 2010

Letters to the editor.  9:750. 2010

Naftifine, a topical allylamine..  9:750. 2010

Results of a National Rosacea Patient Survey: Common issues that concern rosacea sufferers.  8:120-123. 2009

Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): Efficacy, safety, and patient-reported outcomes.  7:245-253. 2008

A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions..  6:1001-1008. 2007

Alefacept in the treatment of psoriatic nail disease: a proof of concept study..  5:339-340. 2006

Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial..  5:646-650. 2006